In details

With the CellClone technologies, potent antibodies against a variety of viruses and bacteria have been identified

Development Pipeline
Utilizing the proprietary CellClone technology platforms, memory B cells and plasma cells of patients who were previously exposed to a specific pathogen are isolated and characterized. A library of monoclonal cell cultures is generated and interrogated using single or multiple high-throughput screening methods.
Memory B cells are immortalized with high efficiency using the Epstein Barr Virus (EBV) in the presence of a toll-like receptor (TLR) agonist, while plasma cells are maintained in single-cell cultures by using interleukin-6 (IL-6) or human mesenchymal stromal cells. In both cases, multiple parallel assays, including functional assays, can be used to identify rare cells that produce antibodies with unique properties. Using these methods, Humabs has isolated potent and broadly neutralizing antibodies against a variety of pathogens. The figure above illustrates the approach.
Given the high throughput and the ability to directly screen for function, rather than just binding to predefined targets, this approach is target agnostic; i.e., unlike classic antibody discovery methods, it does not rely on the prior identification of a defined target antigen.
With the Humabs approach, superior antibodies leading to the neutralization and killing of the pathogen can be identified. This approach significantly accelerates the antibody discovery process, often leading to identification of lead development candidates in a few months, rather than typically more than a year with classic approaches. In the case of Zika virus, for instance, it took only four months from the initial screening of B cells from four immune donors, to the identification and characterization in vitro and in vivo of an exceptionally potent neutralizing antibody that is now being developed for the prevention of Zika virus congenital infections.